ASH Clinical News December 2015 | Page 55

CLINICAL NEWS

for patient, disease, and transplant
characteristics,” the authors concluded.
“Older donor transplantations were
also associated with higher non-relapse
mortality, but donor age was not associated with relapse.”
Given the results of the current
analyses, Dr. Kollman and co-authors
suggest that including donor age in the
adult unrelated donor selection algo-

Measuring Response in GVHD

rithm would optimize survival. However, “optimizing donor selection by blood
ABO matching must be studied further
before definitive recommendations can
be offered.” ●

Clinician Assessment, Patient-Reported Outcomes
Predict Survival

REFERENCE

In patients who have undergone allogeneic hematopoietic cell transplantation
(alloHCT), chronic graft-versus-host
disease (GVHD) is a significant cause of

Kollman C, Spellman SR, Zhang M, et al. The effect of donor characteristics
on survival after unrelated donor transplantation for hematologic
malignancy. Blood. 2015 November 2. [Epub ahead of print]

morbidity and mortality. A major hurdle
in developing new treatments has been
the lack of validated methods of measuring response in clinical trials.

T:7”

Table 4: All Adverse Reactions in ≥5.0% and Grade 3/4 Adverse Reactions
in ≥ 1.0% of Patients in the Rd Continuous or Rd18 Arms*
All Adverse Reactionsa

Table 4: All Adverse Reactions in ≥5.0% and Grade 3/4 Adverse Reactions
in ≥ 1.0% of Patients in the Rd Continuous or Rd18 Arms*

Grade 3/4 Adverse
Reactionsb

Grade 3/4 Adverse
Reactionsb

All Adverse Reactionsa

Rd
Rd
System organ class Continuous Rd18
MPT Continuous Rd18
MPT
Preferred term
(N = 532) (N = 540) (N = 541) (N = 532) (N = 540) (N = 541)

Rd
Rd
System organ class Continuous Rd18
MPT Continuous Rd18
MPT
Preferred term
(N = 532) (N = 540) (N = 541) (N = 532) (N = 540) (N = 541)

Musculoskeletal and connective tissue disorders

Psychiatric disorders

Back painc

170 ( 32) 145 (26.9) 116 (21.4)

37 (7)

34 (6.3)

28 (5.2)

Muscle spasms f

109 (20.5) 102 (18.9) 61 (11.3)

< 1%

< 1%

< 1%

Arthralgia f

101 (19.0) 71 (13.1) 66 (12.2)

9 (1.7)

8 (1.5)

8 (1.5)

Bone pain f

87 (16.4) 77 (14.3) 62 (11.5) 16 (3.0)

15 (2.8)

14 (2.6)

Pain in extremity f 79 (14.8) 66 (12.2) 61 (11.3)

8 (1.5)

8 (1.5)

7 (1.3)

Musculoskeletal
pain f

67 (12.6) 59 (10.9)

36 (6.7)

< 1%

< 1%

< 1%

Musculoskeletal
chest pain f

60 (11.3)

51 (9.4)

39 (7.2)

6 (1.1)

< 1%

< 1%

Muscular
weakness f

43 (8.1)

35 (6.5)

29 (5.4)

< 1%

8 (1.5)

< 1%

40 (7.5)

19 (3.5)

10 (1.8)

< 1%

< 1%

< 1%

90 (16.9) 59 (10.9)

43 (7.9)

9 (1.7)

6 (1.1)

3 (0.6)

33 (6.1)

0 (0.0)

0 (0.0)

0 (0.0)

Neck pain

f

Infections and infestations
Bronchitisc
Nasopharyngitis f

80 (15)

54 (10)

Urinary tract
infection f

76 (14.3) 63 (11.7)

41 (7.6)

8 (1.5)

8 (1.5)

< 1%

Upper respiratory
tract infectionc% f

69 (13.0)

31 (5.7)

< 1%

8 (1.5)

< 1%

Pneumoniac@

93 (17.5) 87 (16.1) 56 (10.4) 60 (11.3) 57 (10.5) 41 (7.6)

53 (9.8)

Respiratory tract
infection%

35 (6.6)

25 (4.6)

21 ( 3.9)

7 ( 1.3)

4 ( 0.7)

1 ( 0.2)

Influenza f

33 (6.2)

23 (4.3)

15 (2.8)

< 1%

< 1%

0 (0.0)

Gastroenteritis f

32 (6.0)

17 (3.1)

13 (2.4)

0 (0.0)

< 1%

< 1%

29 (5.5)

14 (2.6)

16 (3.0)

10 (1.9)

3 (0.6)

3 (0.6)

Rhinitis f

29 ( 5.5)

24 ( 4.4) 14 ( 2.6)

0 (0.0)

0 (0.0)

0 (0.0)

Cellulitisc

< 5%

< 5%

< 5%

8 (1.5)

3 ( 0.6)

2 ( 0.4)

Sepsisc@

33 (6.2)

26-(4.8)

18 (3.3)

26 (4.9)

20 (3.7)

13 (2.4)

Nervous system disorders
Headache f

75 (14.1)

52 (9.6)

56 (10.4)

< 1%

< 1%

< 1%

Dysgeusia f

39 (7.3)

45 (8.3)

22 (4.1)

< 1%

0 (0.0)

< 1%

Blood and lymphatic system disordersd
Anemia

233 (43.8) 193 (35.7) 229 (42.3) 97 (18.2) 85 (15.7) 102 (18.9)

Neutropenia

186 (35.0) 178 (33) 328 (60.6) 148 (27.8) 143 (26.5) 243 (44.9)

Thrombocytopenia 104 (19.5) 100 (18.5) 135 (25.0) 44 (8.3)

43 (8.0)

60 (11.1)

Febrile neutropenia

7 (1.3)

17 (3.1)

15 (2.8)

6 (1.1)

16 (3.0)

14 (2.6)

Pancytopenia

5 (0.9)

6 (1.1)

7 (1.3)

1 (0.2)

3 (0.6)

5 (0.9)

Respiratory, thoracic and mediastinal disorders
Cough f

121 (22.7) 94 (17.4) 68 (12.6)

Dyspneac,e

117 (22.0) 89 (16.5) 113 (20.9) 30 (5.6)

< 1%

< 1%

< 1%

22 (4.1)

18 (3.3)

Epistaxis f

32 (6.0)

31 (5.7)

17 (3.1)

< 1%

< 1%

0 (0.0)

Oropharyngeal
pain f

30 (5.6)

22 (4.1)

14 (2.6)

0 (0.0)

0 (0.0)

0 (0.0)

Dyspnea
exertional e

27 (5.1)

29 (5.4)

< 5%

6 (1.1)

2 (0.4)

0 (0.0)

Metabolism and nutrition disorders
Decreased
appetite

123 (23.1) 115 (21.3) 72 (13.3) 14 (2.6)

7 (1.3)

5 (0.9)

Hypokalemia%

91 ( 17.1) 62 (11.5)

20 (3.7)

11 (2.0)

38 ( 7)

35 (6.6)

Hyperglycemia

62 (11.7)

52 (9.6)

19 (3.5)

28 (5.3)

23 (4.3)

9 (1.7)

Hypocalcemia

57 (10.7) 56 (10.4)

31 (5.7)

23 (4.3)

19 (3.5)

8 (1.5)

Dehydration%

25 ( 4.7)

29 ( 5.4)

17 ( 3.1)

8 (1.5)

13 (2.4)

9 (1.7)

Gout e

< 5%

< 5%

< 5%

8 (1.5)

0 (0.0)

0 (0.0)

Diabetes mellitus% e

< 5%

< 5%

< 5%

8 (1.5)

4 (0.7)

2 (0.4)

Hypophosphatemia e

< 5%

< 5%

< 5%

7 (1.3)

3 (0.6)

1 (0.2)

Hyponatremia% e

< 5%

< 5%

< 5%

7 (1.3)

13 (2.4)

6 (1.1)

139 (26.1) 151 (28.0) 105 (19.4) 39 (7.3)

38 (7.0)

33 (6.1)

Skin and subcutaneous tissue disorders
Rash
Pruritus f

47 (8.8)

49 (9.1)

24 (4.4)

< 1%

< 1%

< 1%
(continued)

147 (27.6) 127 (23.5) 53 (9.8)

4 (0.8)

6 (1.1)

0 (0.0)

Depression

58 (10.9)

10 (1.9)

4 (0.7)

1 (0.2)

46 (8.5)

30 (5.5)

Vascular disorders
Deep vein
thrombosisc%

55 (10.3)

39 (7.2)

22 (4.1)

30 (5.6)

20 (3.7)

15 (2.8)

Hypotensionc%

51 (9.6)

35 (6.5)

36 (6.7)

11 (2.1)

8 (1.5)

6 (1.1)

Injury, Poisoning, and Procedural Complications
Fall f

43 (8.1)

25 (4.6)

25 (4.6)

< 1%

6 (1.1)

6 (1.1)

Contusion f

33 (6.2)

24 (4.4)

15 (2.8)

< 1%

< 1%

0 (0.0)

73 (13.7)

31 (5.7)

5 (0.9)

31 (5.8)

14 (2.6)

3 (0.6)

< 5%

< 5%

< 5%

7 (1.3)

0 (0.0)

0 (0.0)

48 (8.9)

11 (2.1)

4 (0.7)

4 (0.7)

Eye disorders
Cataract
Cataract
subcapsular e
Investigations
Weight decreased
̈
LˍJH